HCV infection prevalence in a population recruited at health centers in Jordan

Hamoudi, Waseem; Ali, Sami Adel Sheikh; Abdallat, Mohammad; Estes, Chris; Razavi, Homie

doi:10.1016/j.jegh.2013.02.003

Cited by 13 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, out of the six seropositive individuals among the HD group, three had HCV viraemia, while none of the controls had HCV viraemia (p=0.081). These findings indicate significantly lower HCV seropositivity rates among HD subjects in Jordan compared with previous studies; HCV seropositivity rates of 28% and 34.6% in 2009 and 2002, respectively, among HD subjects,9 14compared with 0.42% among the general population in 2013 10. This improvement is likely attributable to the better application of HCV screening for donated blood in blood banks, a protocol that was introduced by the Jordanian ministry of health as of 1995, and also likely to the more efficient compliance in application of universal infection control precautions, such as the disinfection of HD machines 15.…”

Section: Discussioncontrasting

confidence: 43%

Increased incidence of BK virus viraemia among patients undergoing chronic haemodialysis: a case–control study

Swedan

2017

J Clin Pathol

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 43%

Increased incidence of BK virus viraemia among patients undergoing chronic haemodialysis: a case–control study

Swedan

2017

J Clin Pathol

View full text Add to dashboard Cite

show abstract

“…Lot of studies explain that the possibility of liver carcinogenesis, despite null replication of HCV, by other pathways. (29)(30)(31) Our data confirms that clearing the viral replication and obtaining SVR does correlate with normalization in liver function tests, as shown in other studies, (32,33) where 100% of our SVR patients had normal Liver tests during the whole period of follow up.…”

Section: Discussionsupporting

confidence: 90%

Durability of Sustained Virological Response and Long Term Follow Up to Pegylated Interferon and Ribavirin in Treated Patients with Chronic Hepatitis C

Hamoudi¹,

Alsmadi²,

Lutfi³

2014

JRMS

Self Cite

View full text Add to dashboard Cite

Objective: To study the clinical, biochemical and virological long-term outcome in chronic hepatitis C patients with a Sustained Virological Response after Pegylated Interferon plus ribavirin combination therapy. Methods: Twenty eight patients with a Sustained Virological Response after treatment with Pegylated Interferon plus ribavirin were included in a 5-year follow-up study in a single Gastroenterology & Hepatology center, based on standard clinical practice. Clinical and ultrasonic evaluation, liver function tests, alpha-fetoprotein and hepatitis C virus RNA by PCR were performed annually for a period of 5 years. Results: The mean follow-up period of the 28 patients was 67 ± 4 months after they obtained a sustained virological response. Eleven patients (39.2%) presented with high fibrosis score (Metavir >3) before treatment. Seventeen patients (60.7%) had genotype 4, nine patients (32.1%) genotype 1, one patient genotype 2 and one patient genotype 3. One patient (3.5%) showed evidence of hepatic decompensation. One patient (3.5%) showed virological relapse after achieving sustained virological response. At the end of the 5-year follow-up there were no deaths, no elevation in liver function tests and no hepatocellular carcinoma. Conclusion: The long-term outcome of patients with sustained virological response to Pegylated Interferon plus ribavirin was maintained in 96.5% with one patient having virological relapse, indicating that Long term recurrence rate to combination therapy was very low.

show abstract

“…All HCV RNA positive individuals in Jordan were infected by a single strain ( S6B Fig ), with 57.7% carrying genotype 4 and 42.3% carrying genotype 1 ( Table 5 ) [ 68 , 103 , 111 , 112 ]. Subtypes 1a and 1b were isolated, respectively, from 54.5% and 45.5% of infected persons with genotype 1.…”

Section: Resultsmentioning

confidence: 99%

The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis

2015

View full text Add to dashboard Cite

ObjectiveTo characterize hepatitis C virus (HCV) epidemiology in countries of the Fertile Crescent region of the Middle East and North Africa (MENA), namely Iraq, Jordan, Lebanon, Palestine, and Syria.MethodsWe systematically reviewed and synthesized available records of HCV incidence and prevalence following PRISMA guidelines. Meta-analyses were implemented using a DerSimonian-Laird random effects model with inverse weighting to estimate the country-specific HCV prevalence among the various at risk population groups.ResultsWe identified eight HCV incidence and 240 HCV prevalence measures in the Fertile Crescent. HCV sero-conversion risk among hemodialysis patients was 9.2% in Jordan and 40.3% in Iraq, and ranged between 0% and 3.5% among other populations in Iraq over different follow-up times. Our meta-analyses estimated HCV prevalence among the general population at 0.2% in Iraq (range: 0–7.2%; 95% CI: 0.1–0.3%), 0.3% in Jordan (range: 0–2.0%; 95% CI: 0.1–0.5%), 0.2% in Lebanon (range: 0–3.4%; 95% CI: 0.1–0.3%), 0.2% in Palestine (range: 0–9.0%; 95% CI: 0.2–0.3%), and 0.4% in Syria (range: 0.3–0.9%; 95% CI: 0.4–0.5%). Among populations at high risk, HCV prevalence was estimated at 19.5% in Iraq (range: 0–67.3%; 95% CI: 14.9–24.5%), 37.0% in Jordan (range: 21–59.5%; 95% CI: 29.3–45.0%), 14.5% in Lebanon (range: 0–52.8%; 95% CI: 5.6–26.5%), and 47.4% in Syria (range: 21.0–75.0%; 95% CI: 32.5–62.5%). Genotypes 4 and 1 appear to be the dominant circulating strains.ConclusionsHCV prevalence in the population at large appears to be below 1%, lower than that in other MENA sub-regions, and tending towards the lower end of the global range. However, there is evidence for ongoing HCV transmission within medical facilities and among people who inject drugs (PWID). Migration dynamics appear to have played a role in determining the circulating genotypes. HCV prevention efforts should be targeted, and focus on infection control in clinical settings and harm reduction among PWID.

show abstract

HCV infection prevalence in a population recruited at health centers in Jordan

Abstract: The study concluded that the prevalence of HCV infection in the population recruited from different health centers in Jordan is relatively low and estimates a prevalence of 0.42% among all age groups and 0.56% among those aged >15 years old.

Cited by 13 publications

References 16 publications

Increased incidence of BK virus viraemia among patients undergoing chronic haemodialysis: a case–control study

Increased incidence of BK virus viraemia among patients undergoing chronic haemodialysis: a case–control study

Durability of Sustained Virological Response and Long Term Follow Up to Pegylated Interferon and Ribavirin in Treated Patients with Chronic Hepatitis C

The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About